Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost

Figures & data

Figure 1 Questionnaire used during the study.

Table 1 Demographic and Baseline Disease Characteristics

Age
N	1872
Mean age ± SD	66.8 ± 12.11
Range	[18–99]
Sex
N	1872
Female	60.9%
Male	38.6%
Missing	0.5%
Intraocular pressure (mmHg)	17.6 ± 4.30
Glaucoma type
N	1872
Primary	85.7%
Secondary	12.1%
Missing data	2.2%
Glaucoma stage
N	3744 eyes
Ocular hypertension	29.9%
Early glaucoma	41.5%
Moderate glaucoma	16.7%
Severe glaucoma	8.3%

Figure 2 Mean tolerability assessed with Visual Analogue Scale in patients receiving PF latanoprost (n=1817). *p<0.01.

Abbreviations: PFL, preservative-free latanoprost; naïve, previously untreated patients.

Figure 3 Ocular signs under previous treatment, preservative-free latanoprost treatment and in naïve patients.

Abbreviations: P, previous treatment; PFL, preservative-free latanoprost; naïve, previously untreated patients.

Figure 4 Corneal and conjunctival fluorescein staining under previous treatment, preservative-free latanoprost treatment and in naïve patients.

Abbreviations: P, previous treatment; PFL, preservative-free latanoprost; naïve, untreated patients.

Figure 5 Conjunctival hyperaemia under previous treatment, preservative-free latanoprost treatment and in naïve patients.

Abbreviations: P, previous treatment; PFL, preservative-free latanoprost; naïve, untreated patients.